Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials
STS, an monoamine oxidase inhibitor antidepressant that potentiates the three major monoamine neurotransmitters (serotonin, norepinephrine, and dopamine), has beneficial therapeutic effects for a spectrum of individual symptoms rated by the HAM-D28 and MADRS. Analyses of specific symptoms assessed by depression rating scales can offer guidance to clinicians in individualizing drug therapy based on presenting symptoms.
Authors
- Dan A. Oren (ORCID: https://orcid.org/0009-0002-4696-9979)
- Andrew Campbell (ORCID: https://orcid.org/0000-0001-9810-1173)
- George I. Moonsammy
- Leigh Anne Nelson (ORCID: https://orcid.org/0000-0003-1481-8682)
- Donald S. Robinson
- Michelle Gilmor (ORCID: https://orcid.org/0000-0001-9421-8278)
- Albert J. Azzaro
- Ying Yang (ORCID: https://orcid.org/0000-0001-7911-0883)
Institutions
- Worldwide Clinical Trials (United States) (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4106
- Citations
- 31
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00